Editor Papa Research April 29, 2019

Extracellular vesicles in hematological malignancies

Extracellular vesicles (EVs) act as transporters that carry restrictive molecules between cells in physiological and pathologic states; so, they play a vital role in occlusion, inflammation, growing, vascular  disfunction and alternative processes that have an effect on the course of hematological diseases. at intervals the tumour microenvironment, as an example the leukemic bone marrow, EVs-mediated communication might direct the activities of close cells and act as a regeneration loop that contributes to cancer progression. The importance of EVs in hematologic malignancies is additionally attributed to their involvement in development of multidrug resistance and therefore the hypercoagulable state associated with hematologic disorders, which can be partly influenced by a rise within the total range of EVs. during this review, we tend to centered on the role of EVs in hematological malignancies and particularly on their influence on the BM microenvironment, their role in growing and therefore the doable use of EVs as biomarkers of sickness progression and drug resistance. [1]

Sexual dimorphism in solid and hematological malignancies

Cancer represents a number one reason behind death with incessantly increasing incidence worldwide. several solid cancer sorts in non-reproductive organs are considerably a lot of frequent and deadly in males compared to females. This sex-biased distinction is additionally gift in medical specialty malignancies. during this review, we tend to gift an summary concerning sex variations in cancer with a spotlight on leukaemia. we tend to discuss mechanisms probably underlying the determined sex-biased imbalance in cancer incidence and outcome as well as sex hormones, sex chromosomes, and immune responses. Besides touching the pathobiology of cancers, sex variations also can influence drug responses, most notably those to immune stop blockers. Therefore, sex ought to become a relevant consider trial style so as to avoid over- or under-treatment of 1 sex. [2]

Palliative Care in Patients with Hematological Malignancies

Patients with hematological malignancies (HM) today seldom receive palliative or hospice care, and studies on potential effects of integrated palliative care are rare. This narrative review provides a comprehensive summary on their current end-of-life care, 1st knowledge on integrated specialist palliative care (SPC) and potential barriers. Symptom burden and distress in patients with hectometer appear to be resembling alternative cancer patients, however their performance standing and specific symptoms are even worse. Prolongation of life sometimes remains the most focus till the last days or weeks of life. Their probability to die in hospital is double as high, however their probability to receive specialist palliative or hospice care is simply 1/2 that of alternative cancer patients. Prospective studies indicate a high acceptableness and positive effects of integrated SPC, e.g. clarification of treatment goals, stabilization of quality of life, diminished depression, anxiety, symptom burden, and post-traumatic stress disorders. knowledge base cooperation, timely discussions concerning SPC referral, and indicators to ‘flag’ patients in want for SPC are necessary, however they’re mostly missing. finally, additional studies must valuate factors distinctive patients with hectometer in want for SPC. additional models of early integrated palliative care ought to be evaluated in prospective studies and established in daily clinical apply. [3]

Impact of body mass index at different transplantation stages on postoperative outcomes in patients with hematological malignancies: a meta-analysis

Although the association between body mass index (BMI) and overall survival (OS) has been reported  in leukaemia patients of various ages, whether or not BMI levels at completely different stages of haematopoietic vegetative cell transplantation (HSCT) have different effects on surgical  survival remains moot. we have a tendency to searched four electronic databases from origin through Gregorian calendar month 2017 with none language restrictions and enclosed studies on differing kinds of haematological malignancies news each BMI time points and HSCT. Of the 1420 articles known, twenty six articles were eligible for inclusion during this meta-analysis. 3 weight teams (obese, overweight and underweight) were separately compared with the conventional cluster. outline risk estimates for OS and event-free survival (EFS) were calculated with random- or fixed-effects models. For BMI at the pre-HSCT stage, a statistically vital positive association of hyperbolic risk of OS (RR: one.17; ninety five CI: one.08–1.27) and EFS (RR: one.29; ninety five CI: 1–1.67) was known in lean people compared with those with traditional weights. For BMI within the HSCT stage, a lower BMI was considerably related to poorer OS (RR: one.34; ninety five CI: one.01–1.78) and EFS (RR: one.53; ninety five CI: one.09–2.06) compared with a standard BMI. Our results indicated that lower BMI at the pre-HSCT stage or throughout HSCT is related to poorer survival.[4]

Comparative Study between Anthracycline Based Regimen and Taxane Based Regimen in Metastatic Gastric Cancer

Introduction: Taxanes and anthracyclin containing regimes are the foremost winning regimens in advanced stomachic cancer with comparable results however with totally different toxicity profiles.

Objective: to check effectiveness and toxicity of two regimens one containing anthrathycline (ECSF regimen) and different contain taxane (PCF regimen) as a primary line medical care in advanced stomachic cancer.

Methods: Between might 2011 and Dec 2015, a complete  of one hundred twenty patients with regionally advanced and pathological process stomachic carcinoma were enclosed within the study, sixty patients received  ECSF (Epirubicin fifty mg/m2 iv  d1, Cisplatin sixty mg/m2 iv d1, 5-FU 1750 mg/m2/d “1 and 8” CIVI over twenty four h, Folinic acid two hundred mg /m2 day one, eight recurrent each three weeks), while, another sixty patients received PCF (Paclitaxel a hundred and fifty mg/m2 IV on day 1; Cisplatin fifteen mg/m2 IV on days 1-5 and 5-FU 600mg/m2/day CIVI  d1-5 each three weeks) till sickness progression or unacceptable toxicities.

Results: hockey player of ECSF was superior to PCF arm, 47% vs. thirty four severally p = zero.001. The toxicity profiles were less in ECSF arm than PCF arm particularly in leucopenia and mucositis. Median PFS and OS were considerably higher in ECSF arm than PCF (6.9 vs. 4.9 months p= zero.022) and (11.1 vs.8.9 months p = zero.028) severally.

Conclusion: the utilization of anthracycline based mostly plan as initial line medical care in advanced stomachic cancer showed higher outcome and acceptable toxicity once it compared with paclitaxel containing regimen. [5]


[1] Litwińska, Z., Łuczkowska, K. and Machaliński, B., 2019. Extracellular vesicles in hematological malignancies. Leukemia & lymphoma, 60(1), pp.29-36. (Web Link)

[2] Ben-Batalla, I., Vargas-Delgado, M.E., Meier, L. and Loges, S., 2019, March. Sexual dimorphism in solid and hematological malignancies. In Seminars in immunopathology (Vol. 41, No. 2, pp. 251-263). Springer Berlin Heidelberg. (Web Link)

[3] Oechsle, K., 2019. Palliative care in patients with hematological malignancies. Oncology research and treatment, 42. (Web Link)

[4] Impact of body mass index at different transplantation stages on postoperative outcomes in patients with hematological malignancies: a meta-analysis

Guangxu Ren, Wei Cai, Liping Wang, Jiazhang Huang, Suqin Yi, Lingang Lu & Jing Wang

Bone Marrow Transplantationvolume 53, pages708–721 (2018) (Web Link)

[5] Ibrahim, A., A. Salem, M. and Hefny, A. (2017) “Comparative Study between Anthracycline Based Regimen and Taxane Based Regimen in Metastatic Gastric Cancer”, Journal of Cancer and Tumor International, 5(1), pp. 1-8. doi: 10.9734/JCTI/2017/32058. (Web Link)

Leave a comment.

Your email address will not be published. Required fields are marked*

WP2Social Auto Publish Powered By : XYZScripts.com